Heart Transplant As Therapy For An Unresectable Recurrent Cardiac Fibroma
HFSA ePoster Library. Hernandez Mejia L. 09/10/21; 343421; 192
Luis Hernandez Mejia
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Discussion Forum (0)
Background: Approximately 50% of heart failure (HF) cases diagnosed in the US is HF with preserved ejection fraction (HFpEF). The incidence of HFpEF increases annually and is associated with significant morbidity and mortality. Despite the increasing mortality, treatment options are limited. Beta-blockers (BB) have a significant mortality benefit in HF with reduced ejection fraction (HFrEF) but little is known regarding benefit in HFpEF. In this study we retrospectively analyzed the effect of BB on all-cause mortality in patients with HFpEF.
Methods: This is a retrospective cohort study performed at a single academic center including patients admitted for a HF diagnosis between January 2011 and March 2020. Demographic information, clinical characteristics, and Charlson Deyo comorbidity scores were extracted from the EMR. Baseline differences were tested using Anova tests for continuous variables and chi-squared tests for categorical variables. Survival is reported using Kaplan-Meier curves at 30 days and 1 year; Cox proportional-hazards models are used to compute hazard ratios for BB versus non-BB groups for each endpoint. All statistical analyses were performed using SAS version 9.4.
Results: Table 1 shows all-cause mortality for BB and non-BB groups in patients with EF 40-55% and > 55% at 30 days and 12 months. BB group had no significant 30-day all-cause mortality benefit in patients with EF > 55%. When adjusted by Charlson Deyo comorbidity index, there was significant mortality benefit. In patients with EF > 55% on BB, there was significant mortality benefit at 12 months [Figure 1]. In patients with EF 40-55%, there was significant mortality benefit at 30 days and 12 months [Figure 2].
Conclusion: For patients with an EF of 40 - 55% and > 55%, Beta-blocker use showed significant mortality benefit.
Methods: This is a retrospective cohort study performed at a single academic center including patients admitted for a HF diagnosis between January 2011 and March 2020. Demographic information, clinical characteristics, and Charlson Deyo comorbidity scores were extracted from the EMR. Baseline differences were tested using Anova tests for continuous variables and chi-squared tests for categorical variables. Survival is reported using Kaplan-Meier curves at 30 days and 1 year; Cox proportional-hazards models are used to compute hazard ratios for BB versus non-BB groups for each endpoint. All statistical analyses were performed using SAS version 9.4.
Results: Table 1 shows all-cause mortality for BB and non-BB groups in patients with EF 40-55% and > 55% at 30 days and 12 months. BB group had no significant 30-day all-cause mortality benefit in patients with EF > 55%. When adjusted by Charlson Deyo comorbidity index, there was significant mortality benefit. In patients with EF > 55% on BB, there was significant mortality benefit at 12 months [Figure 1]. In patients with EF 40-55%, there was significant mortality benefit at 30 days and 12 months [Figure 2].
Conclusion: For patients with an EF of 40 - 55% and > 55%, Beta-blocker use showed significant mortality benefit.
Background: Approximately 50% of heart failure (HF) cases diagnosed in the US is HF with preserved ejection fraction (HFpEF). The incidence of HFpEF increases annually and is associated with significant morbidity and mortality. Despite the increasing mortality, treatment options are limited. Beta-blockers (BB) have a significant mortality benefit in HF with reduced ejection fraction (HFrEF) but little is known regarding benefit in HFpEF. In this study we retrospectively analyzed the effect of BB on all-cause mortality in patients with HFpEF.
Methods: This is a retrospective cohort study performed at a single academic center including patients admitted for a HF diagnosis between January 2011 and March 2020. Demographic information, clinical characteristics, and Charlson Deyo comorbidity scores were extracted from the EMR. Baseline differences were tested using Anova tests for continuous variables and chi-squared tests for categorical variables. Survival is reported using Kaplan-Meier curves at 30 days and 1 year; Cox proportional-hazards models are used to compute hazard ratios for BB versus non-BB groups for each endpoint. All statistical analyses were performed using SAS version 9.4.
Results: Table 1 shows all-cause mortality for BB and non-BB groups in patients with EF 40-55% and > 55% at 30 days and 12 months. BB group had no significant 30-day all-cause mortality benefit in patients with EF > 55%. When adjusted by Charlson Deyo comorbidity index, there was significant mortality benefit. In patients with EF > 55% on BB, there was significant mortality benefit at 12 months [Figure 1]. In patients with EF 40-55%, there was significant mortality benefit at 30 days and 12 months [Figure 2].
Conclusion: For patients with an EF of 40 - 55% and > 55%, Beta-blocker use showed significant mortality benefit.
Methods: This is a retrospective cohort study performed at a single academic center including patients admitted for a HF diagnosis between January 2011 and March 2020. Demographic information, clinical characteristics, and Charlson Deyo comorbidity scores were extracted from the EMR. Baseline differences were tested using Anova tests for continuous variables and chi-squared tests for categorical variables. Survival is reported using Kaplan-Meier curves at 30 days and 1 year; Cox proportional-hazards models are used to compute hazard ratios for BB versus non-BB groups for each endpoint. All statistical analyses were performed using SAS version 9.4.
Results: Table 1 shows all-cause mortality for BB and non-BB groups in patients with EF 40-55% and > 55% at 30 days and 12 months. BB group had no significant 30-day all-cause mortality benefit in patients with EF > 55%. When adjusted by Charlson Deyo comorbidity index, there was significant mortality benefit. In patients with EF > 55% on BB, there was significant mortality benefit at 12 months [Figure 1]. In patients with EF 40-55%, there was significant mortality benefit at 30 days and 12 months [Figure 2].
Conclusion: For patients with an EF of 40 - 55% and > 55%, Beta-blocker use showed significant mortality benefit.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}